Is Pharma R&D evolving fast enough?

How Evolutionary Economics Is Shaping the Future of Pharmaceutical Research & Development?

The pharmaceutical industry faces a growing R&D productivity crisis. Despite heavy investments, the return on research has been diminishing. Companies are shifting strategies to maintain their competitive edge in a rapidly evolving environment, increasingly relying on technological advances and adapting their business models to remain sustainable.

The article draws on evolutionary economics to frame the changes in pharmaceutical R&D. Similar to biological evolution, firms in this sector must adapt to external pressures, such as market forces, scientific progress, and regulatory changes. Successful firms generate innovations, which are selected through competitive market forces, while others may stagnate or fail. This evolutionary process is driven by three key mechanisms:

1. Variation: Pharmaceutical companies generate innovations (technological or structural changes) in response to challenges or new opportunities.

2. Selection: Innovations are tested and filtered by external pressures like market competition, regulation, and technological advancement. Firms with more successful innovations thrive.

3. Replication: Successful innovations and strategies are adopted and replicated by others, ensuring continued growth for companies that adapt effectively.

As the R&D model of large pharmaceutical companies (often based on small-molecule drug discovery) encounters increasing costs and low success rates, these companies have been exploring alternative strategies. Leading pharmaceutical firms are adopting hybrid models that combine internal R&D with external innovations from biotech firms, universities, and research institutions. This shift has led to two potential future business models:

1. AIPCO (Asset-Integrating Pharma Company): Focused on acquiring and integrating external assets, particularly biotech innovations, later in the R&D process. These companies are market-driven and prioritize commercialization and lifecycle management over early-stage research.

2. TIPCO (Technology-Investigating Pharma Company): These companies focus on early-stage, technology-driven research, aiming to pioneer first-in-class drugs. TIPCOs are deeply integrated with cutting-edge technologies like AI, gene editing, and other biotech advancements.

Emerging technologies are central to the future of pharmaceutical R&D. Innovations like artificial intelligence (AI), machine learning, and gene editing are revolutionizing drug discovery, improving efficiencies, and allowing firms to explore previously untapped avenues for drug development. For example, AI can accelerate target identification and predict protein structures, while CRISPR gene editing enables the precise alteration of genetic material, offering potential cures for previously untreatable diseases.

Additionally, AI-driven clinical trials and digital patient recruitment are making trials faster and more efficient, potentially reducing the need for costly in-vivo experiments. These technological tools are reshaping how pharmaceutical companies approach drug discovery, allowing them to streamline processes and reduce R&D costs.

Several factors are influencing the evolution of pharmaceutical R&D:

1. Regulatory Changes: New laws like the Inflation Reduction Act are shifting how drug prices are controlled, particularly for treatments reimbursed through government programs. This will likely push companies to focus on more complex, biological therapies, less affected by price negotiations.

2. Market Disruptions: The COVID-19 pandemic served as a significant selection mechanism. It tested the pharmaceutical industry's ability to adapt quickly and innovate in response to urgent global health challenges. This experience demonstrated the importance of flexibility, open collaboration, and the ability to rapidly advance drug development.

3. External Competition: The entry of tech giants like Google, Apple, and Amazon into the healthcare space adds new pressures on traditional pharma companies. These tech companies are leveraging their expertise in AI, data science, and machine learning to enhance drug discovery processes, creating competition that pharmaceutical firms must contend with.

The article concludes with a look forward to how pharmaceutical companies might evolve. The next generation of pharma firms will likely have to integrate new technologies and external innovations into their operations to remain competitive. Companies will need to enhance their ability to adapt, leveraging technologies like AI, digital platforms, and biotechnology to gain a competitive edge. Whether companies will succeed depends on their ability to develop new capabilities, such as dynamic capabilities to adapt to changing environments, and absorptive capacities to integrate new knowledge.

The pharmaceutical industry is at a crossroads. R&D productivity is critical, and firms must innovate to keep up with technological advances. Whether they embrace models like AIPCO or TIPCO, pharmaceutical companies must be prepared for continuous adaptation. The future will likely see more collaborative efforts between biotech firms, large pharma companies, and even tech giants, as they seek to optimize their R&D processes and reduce the costs and risks involved.

Full article: 

https://www.sciencedirect.com/science/article/pii/S1359644624003477

Disclaimer: This post provides a summary of research articles for informational purposes. We do not own the content linked here, and access may require a subscription. Please refer to the sources for full details.